The abstract is read at the publisher; the summary is JClub's.
In 33 patients with Fusobacterium nucleatum–positive, microsatellite-stable metastatic colorectal cancer, tislelizumab plus fruquintinib and metronidazole achieved a median progression-free survival of 6.0 months.
- Why it matters: Fusobacterium nucleatum is linked to chemoresistance and immune evasion in CRC, yet targeted therapeutic options are limited, especially for microsatellite-stable metastatic disease.
- What they did: In a multicenter single-arm phase 2 trial (NCT06356597), patients received tislelizumab, fruquintinib, and metronidazole; metagenomic profiling assessed Fusobacterium nucleatum abundance and exploratory microbiome signals.
- The result: The objective response rate was 19.4% with a 83.9% disease control rate, metronidazole reduced Fusobacterium nucleatum abundance, and fecal microbiota transplantation from responders sensitized germ-free mice by enhancing cytotoxic CD8+ T cell differentiation and reducing terminal exhaustion.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.